BioCentury
ARTICLE | Financial News

Indi Molecular raises $11.5M in series A round

June 29, 2017 6:29 PM UTC

Indi Molecular Inc. (Culver City, Calif.) said it raised $11.5 million in a series A round led by M Ventures, the venture arm of Merck KGaA (Xetra:MRK). Also participating were Legend Capital, Sabey Corp. (Seattle, Wash.), and Asset Management Ventures.

Indi uses its protein-catalyzed capture (PCC) platform to produce synthetic peptides that could be used as in vivo imaging agents and in vitro diagnostics when low target immunogenicity or suboptimal pharmacokinetics limit the utility of mAbs. The platform uses click chemistry to build PCC agents that mimic the binding specificity and affinity of mAbs, but with biochemical properties similar to small molecules such as stability and size (see BioCentury, March 31, 2014)...

BCIQ Company Profiles

Indi Molecular Inc.